Tag: Uppsala University Sweden
Oncolytic Virus Clinical Trial for Neuroendocrine Tumor Patients Begins at Uppsala University, Sweden
It is with great excitement that we share the announcement of the start of the AdVince clinical trial for neuroendocrine cancer patients at Uppsala University in Sweden – the oncolytic virus is on its way to the first patient in the trial!!
9 More News Items for the Carcinoid and Neuroendocrine Cancer Community
Carcinoid/neuroendocrine cancer specialist Dr. Eric Liu will be joining the Rocky Mountain Cancer Centers in Denver, Colorado, effective June 1, 2015. He and medical oncologist Dr. Allen Cohn, also from Rocky Mountain Cancer Centers, will head up …READ MORE
New Jersey Carcinoid Cancer NETwork Conference in November, Registration through October 16
Three of the country’s leading carcinoid and neuroendocrine cancer specialists will be featured speakers for the New Jersey Carcinoid Cancer NETwork Conference. to be held on Saturday, November 2, 2013 at the Crowne Plaza in Edison, New Jersey. Carcinoid/NETs: …READ MORE
A Possible Cure for Neuroendocrine Cancer: Exciting Update!
Back in September 2012 we shared the following: “For $1.6 million (1 million pounds) an oncolytic virus that has the potential to cure neuroendocrine cancer can be named for the donor. At Uppsala University in Sweden researchers are ready to start a …READ MORE
Archived Neuroendocrine Tumor Webinar by Dr. Eric Liu Now Available
Dr. Eric H. Liu, Director of the Neuroendocrine Center and Director of Surgical Services at Vanderbilt University Medical Center in Tennessee, presented a live webinar on August 22, 2012 entitled Imaging of Neuroendocrine Tumors and Obstacles to Diagnosis.…READ MORE
A Possible Cure for Neuroendocrine Cancer — It Can Be Named for You or a Loved One
For $1.6 million (1 million pounds) an oncolytic virus that has the potential to cure neuroendocrine cancer can be named for the donor. At Uppsala University in Sweden researchers are ready to start a clinical trial for up to 20 NET (neuroendocrine tumor)…READ MORE